Stock Events

Stock Events

Salarius Pharmaceuticals 

$0.8400
44
+$0.19+29.23% Wednesday 21:00
-$0.01-1.18%Thursday 00:59Pre-market

Statistics

Day High
0.8976
Day Low
0.6865
52W High
44.1
52W Low
0.5148
Volume
5,962,438
Avg. Volume
3,777,690
Mkt Cap
4.92M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12NovExpected
Q3 2025
Q1 2026
Q2 2026
Next
-403.2
-269.76
-136.32
-2.88
Expected EPS
-3.1224
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-11.15MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.38B
BioMarin Pharmaceutical develops and commercializes innovative therapies for rare genetic diseases, overlapping with Salarius' focus on rare cancers.
CRISPR Therapeutics
CRSP
Mkt Cap5.47B
CRISPR Therapeutics is involved in gene editing, a cutting-edge technology that could address cancer in ways competitive to Salarius' approach.
Novartis
NVS
Mkt Cap266.8B
Novartis offers a broad portfolio of oncology drugs, directly competing with Salarius Pharmaceuticals in the cancer treatment market.
Gilead Sciences
GILD
Mkt Cap186.13B
Gilead Sciences has a strong presence in oncology and cell therapy, areas that Salarius is also targeting.
AMGEN
AMGN
Mkt Cap208.49B
Amgen has a diverse oncology portfolio, including treatments for rare cancers, making it a direct competitor.
Pfizer
PFE
Mkt Cap157.65B
Pfizer has a large and expanding oncology division, competing across a range of cancer treatments, including those for rare cancers.
Merck
MRK
Mkt Cap362.35B
Merck is known for its cancer treatments, including immunotherapies that compete with Salarius' therapeutic approaches.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.8B
Regeneron Pharmaceuticals, with its focus on innovative biologics for cancer treatment, competes in the same biopharmaceutical space as Salarius.

About

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
Show more...
CEO
Mr. Mark J. Rosenblum CPA
Employees
2
Country
United States
ISIN
US79400X4043

Listings

STU
DE
FP11.STU
MU
DE
FP11.MU
XNAS
US
DCOY
BOATS
BOATS
DCOY.BOATS

0 Comments

Share your thoughts

FAQ

What is Salarius Pharmaceuticals stock price today?▼
The current price of SLRX is $0.84 USD — it has increased by +29.23% in the past 24 hours. Watch Salarius Pharmaceuticals stock price performance more closely on the chart.
What is Salarius Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Salarius Pharmaceuticals stocks are traded under the ticker SLRX.
Is Salarius Pharmaceuticals stock price growing?▼
SLRX stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Salarius Pharmaceuticals has showed a -78.73% decrease.
What is Salarius Pharmaceuticals market cap?▼
Today Salarius Pharmaceuticals has the market capitalization of 4.92M
What is Salarius Pharmaceuticals revenue for the last year?▼
Salarius Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Salarius Pharmaceuticals net income for the last year?▼
SLRX net income for the last year is -11.15M USD.
How many employees does Salarius Pharmaceuticals have?▼
As of September 25, 2026, the company has 2 employees.
In which sector is Salarius Pharmaceuticals located?▼
Salarius Pharmaceuticals operates in the Health & Wellness sector.
When did Salarius Pharmaceuticals complete a stock split?▼
The last stock split for Salarius Pharmaceuticals was on August 18, 2025 with a ratio of 1:15.
Where is Salarius Pharmaceuticals headquartered?▼
Salarius Pharmaceuticals is headquartered in Houston, United States.